Sugi Predict

Sugi Predict / Compounds / SCHEMBL424263

SCHEMBL424263

SCHEMBL424263

O=C(O)c1ccc(C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 2/20 0.78
▸ ALDH1A1 P00352 3/20 0.67
▸ HPGD P15428 3/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ HSD17B10 Q99714 2/20 0.67
▸ USP2 O75604 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ FLT1 P17948 1/20 0.50
▸ FLT4 P35916 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ RXRA P19793 2/20 0.49
▸ RXRB P28702 2/20 0.49
▸ GRIK1 P39086 1/20 0.49
▸ RXRG P48443 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ ALOX12 P18054 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ AVPR2 P30518 1/20 0.48
▸ GPR27 Q9NS67 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17470866 0.86 CES2 (0.59) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL503272 0.86 CES2 (0.75) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL11805874 0.86 CES2 (0.75) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL460066 0.85 KDM4E (0.69) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL937022 0.84 CES2 (0.72) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL30481870 0.84 CES2 (0.72) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL1996550 0.84 CES2 (0.72) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL1002163 0.84 CES2 (0.72) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL30518051 0.84 CES2 (0.72) CES2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL27637456 0.83 CES2 (0.56) CES2ALDH1A1HPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 — — US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 — — EP claimed
EP-3551634-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 — — EP claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 — — US claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US claimed
WO-2018108231-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 — — WO claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
EP-0442340-B1 Process for the preparation of an organolithium compound starting from 1,3-bis(trifluoromethyl)-benzene HOFFMANN LA ROCHE (CH) 1995-02-22 — — EP claimed
US-5162577-A Chemical intermediates HOFFMANN-LA ROCHE INC. (US) 1992-11-10 — — US claimed
EP-0442340-A2 Process for the preparation of an organolithium compound starting from 1,3-bis(trifluoromethyl)-benzene F. HOFFMANN-LA ROCHE AG (CH) 1991-08-21 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS CES2 594/4885ALDH1A1 3087/4885HPGD 3676/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 CES2 1598/4885ALDH1A1 1569/4885HPGD 3145/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 CES2 2351/4885ALDH1A1 1723/4885HPGD 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.